Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

Kausik K Ray,R Scott Wright,David Kallend,Wolfgang Koenig,Lawrence A Leiter,Frederick J Raal,Jenna A Bisch,Tara Richardson,Mark Jaros,Peter L J Wijngaard,John J P Kastelein,ORION-10 and ORION-11 Investigators,David G Kallend,David Waters,Terje Pedersen,Eva Lonn,Ian Ford,James Kopp,Michael Adams,Linda Murray,Charles Michieli,Jeffery DeGrauw,William Ellison,Leslie Tharenos,Stephen Halpern,Michele Reynolds,Michael Noss,Gary Korff,Stephen Canowitz,Randall Severance,Douglas Schumacher,William Kirby,Jeffrey Klein,Rickie Conrady,Tami Wahlin,Robert Lending,Michael Harper,Jennifer Kay,Mehrdad Ariani,John Scott,Ahmed Arif,Mohammad Shoukfeh,Bogdan Gheorghiu,Matthew Teltser,Timothy Crater,David Ramstad,Sara Llerena,Anwar Ahmad,Krishnamoorthy Vivekananthan,Jeffrey Wayne,Neil Fraser,Dennis Levinson,Jeffrey Geohas,Barry McLean,Sady Alpizar,John Evans,Robert Buynak,Michael Seep,Sashi Makam,Ramachandra Patak,Matthew Budoff,Ahmad Aslam,Stephen Jones,Seth Baum,Alvaro Murcia,Hessam Aazami,Jalal Abbas,Jeffrey Anderson,David Bouda,Robert Busch,Robert Falcone,Leslie Forgosh,Randal Jacks,John LeDoux,Steven Lupovitch,Sharan Mahal,Joe Pouzar,Priyavadan Shah,Thomas Stuckey,Suhail Zavaro,Jose Cardona,Mahesh Changlani,Winston Gandy,Bernard Garcia,William Jennings,Norman Lepor,James Lovell,Ronald Mayfield,Howard Rubenstein,Gerald Shockey,Stuart Stoller,Joseph Szcytowski,Antonio Terrelonge,Jorge Venereo,Phillip Toth,Laura Akright,Mahesh Amin,Nabil Andrawis,Anthony Captain,Anurekha Chadha,Ankur Doshi,Jonathan Fialkow,Ferris George,Timberly Gilford,Ashwini Gore,Tariq Haddad,Aaron Hartman,Sandeep Khurana,Michael Koren,Srikanth Malempati,Joaquin Martinez-Arraras,Mark Napoli,Brien Peirpont,Drew Purdy,Erich Schramm,Alfred Tan,Charles Treasure,Kishor Vora,Jonathan Waltman,Andrew Waxler,James Wild,Jonathan Bornfreund,Atoya Adams,Saadat Ansari,Sabrina Benjamin,Kenneth Blaze,Cristian Breton,Thomas Carlson,Evelyne Davidson,William Davila,Philip Diller,Frank Eder,Mahfouz El-Shahawy,Roger Estevez,Neil Farris,David Henderson,James Holler,Mumtazuddin Zubair Jafar,Curtis Jantzi,Vicki Kalen,Daniel Koontz,Padma Mangu,Brock Merritt,Alan Miller,Nidal Morrar,Edward Pereira,Jorge Posada,William Randall,Lilia Rodriguez Ables,Saihari Sadanandan,Satinder Saini,Bruce Seaton,Charles Sharpe,Pamela Stearns,Sanjay Vora,Michelle Welch,Mohamed El-Shahawy,Robert Lipetz,Traci Turner,Jorge Navas,George Kichura,Phyllis Marx,Jan Malecha,Antonin Dufka,Katrin Arelin,Suresh Yadav,Christel Contzen,Liana Vismane,Manuela Licka,Károly Nagy,Csaba Hajdú,Karoly Wittmann,Csilla Nemeti,Malgorzata Duszynska,Anna Sidorowicz-Bialynicka,Piotr Rozpondek,Malgorzata Jagielska-Plata,Jolanta Krzykowska,Dorota Knychas,Elzbieta Blach,Robert Glowka,Jerzy Pregowski,Donald Drozdz,Renata Bijata-Bronisz,Danuta Wronska,Rafal Sztembis,Jaroslaw Trebacz,Boguslaw Derlaga,Marek Styczkiewicz,Bozena Zieba,Teresa Rusicka,Janusz Spyra,Lesley Burgess,Nyda Fourie,Dorothea Urbach,Thomas Coetzer,Elane Nieuwenhuizen,Landman Lombard,Yacoob Vahed,Suzanne Blignaut,Inna Sorokina,Oleksandra Donets,Halyna Myshanych,Oleksandr Kovalov,Anna Kulyk,Myroslava Vayda,Orest Abrahamovych,Vira Tseluyko,Roman Stets,Imrozia Arif,Nicoletta Sulli,Devina Weeraratne,Yieng Huong,Madhu Venkate Gowda,Christina Kyriakidou,Hawys Thomas,Adrian Renouf Adrian,Mark Blagden,Rehan Symonds,Mahadev Ramjee,Timothy Hall,Ian Collyer,Philip Stratford-Smith,Paul Jackson,Grainne Breen,Keith Richardson,Stephen Tomkinson,Simon De Vial,Samina Ashraf,Peter Wilson

DOI: https://doi.org/10.1056/NEJMoa1912387

2020-04-16

Abstract:Background: Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. Methods: We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter over a period of 540 days. The coprimary end points in each trial were the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. Results: A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, respectively. Mean (±SD) LDL cholesterol levels at baseline were 104.7±38.3 mg per deciliter (2.71±0.99 mmol per liter) and 105.5±39.1 mg per deciliter (2.73±1.01 mmol per liter), respectively. At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. Conclusions: Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).